Skip to content

Efficacy Stem Cell in Treatment Autism

Efficacy and Safety of Augmenting Autologous Bone Marrow Stem Cell Therapy in Routine Treatment of Children with Autism Spectrum Disorder: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201512315280N22
Enrollment
36
Registered
2016-05-28
Start date
2015-04-04
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism. Childhood autism

Interventions

Intervention 1: In intervention group stem cell intratechal transplantation is doing augmentation of usual treatment. Intervention 2: In control group Patients get routine treatment .

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 15 Years

Inclusion criteria

Inclusion criteria: age range of =5 and =15 years a definite diagnosis of ASD based on DSM

Exclusion criteria

Exclusion criteria: a long history of allergic reactions seizures during the past six months brain trauma moderate to severe extrapyramidal symptoms and tardive dyskinesia severe self-injury behavior autoimmune diseases severe hematologic and pulmonary disease (such as pneumonia, asthma, malignancy and immune deficiency) severe focal or systemic infection (such as AIDS, hepatitis and syphilis) kidney and liver problems anemia and hemoglobin level less than 8 g/dL bone marrow- associated diseases receiving other treatments affecting the health of stem cell therapy

Design outcomes

Primary

MeasureTime frame
Autism. Timepoint: Baseline, 1, 3, 12 months. Method of measurement: GARSII test.;Autism. Timepoint: Baseline, 1, 3, 12 months. Method of measurement: CARS test.;Illness severity. Timepoint: Baseline, 1, 3, 12 months. Method of measurement: Clinical Global Impression (CGI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Narges Sharifzadeh

Mashhad University of Medical Sciences

narges.sharifzadeh@gmail.com+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026